ArriVent Pharmaceuticals Science
Pipeline
CandidateCand
IndicationInd
PreclinicalPre
Phase 1Ph1
Phase 2Ph2
Phase 3Ph3
PartnersPart
Small molecule, pan-EGFR mutant selective TKI
Advanced or Metastatic NSCLC

Furmonertinib

Phase 1b

Small molecule,
pan-EGFR mutant
selective TKI

Advanced or Metastatic NSCLC
Allist logo
Undisclosed
Solid Tumors

ARR-002

Undisclosed

Solid Tumors
AARVIK logo

At ArriVent,

we understand that human cancer is a complex set of diseases which requires diverse therapeutic approaches to provide the most benefit to patients. For that reason, we are therapeutic-class agnostic in our ability to identify and rapidly develop innovative medicines for cancer patients regardless of where the drug was initially discovered. We leverage our scientific knowledge and broad experience in oncology drug development to identify first-in-class and/or best-in-class medicines with strong development potential, and work seamlessly with scientific founders and their companies to bring these drugs to patients globally as quickly as possible.

Our lead clinical asset furmonertinib is an example of how we are building our pipeline based on a strong understanding of cancer biology and unmet medical need, and we are applying these same skills to other medicines and research collaborations as well.